A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
From MaRDI portal
Publication:6627403
DOI10.1002/sim.8528zbMATH Open1546.62435MaRDI QIDQ6627403
Pavlos Msaouel, Peter F. Thall, Juhee Lee
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Bayesian designadaptive randomizationdose findinginterim responsemixed hazardphase I--II clinical trial
Cites Work
- Unnamed Item
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- On semi-competing risks data
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Frailty-Based Competing Risks Model for Multivariate Survival Data
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Analysis of multivariate probit models
- A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III
- Cumulative and CUB Models for Rating Data: A Comparative Analysis
- Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times
This page was built for publication: A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
